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Abstract
Pheochromocytomas and paragangliomas are rare tumors, characterized by catecholamine 
synthesis, release, and metabolism, with the same embryological origin. Pheochromocytomas 
develop from chromaffin cells of the adrenal medulla, whereas paragangliomas arise extra-
adrenal from sympathetic and parasympathetic nervous chains. During the past 10 years, 
there have been significant advances in the understanding of these tumors as it is now 
known that 30–40% of pheochromocytomas and paragangliomas have an underlying 
genetic cause. Pheochromocytomas and paragangliomas have classically been associated 
with three syndromes: von Hippel-Lindau (VHL), multiple endocrine neoplasia type 2 
(MEN 2), and neurofibromatosis type 1 (NF1). To date, more than 21 gene mutations 
have been identified that are involved in the development of these tumors. Identification 
of such gene mutations associated with pheochromocytomas and paragangliomas will 
ensure early diagnosis, prompt treatment, and better prognosis for patient and family 
members. The recent developments in molecular pathogenesis of pheochromocytomas 
and paragangliomas will provide future treatment options toward personalized therapy 
for patients. This chapter summarizes the most important aspects of genetics and clinical 
characteristics, together with a focus on the new susceptibility genes.
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1. Introduction
The tumor classification system by the World Health Organization (WHO) in 2004 defines 
pheochromocytomas as catecholamine-secreting tumors originating from chromaffin cells 
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found in the medulla of adrenal glands, and paragangliomas as extra-adrenal tumors 
developing from ganglia along the sympathetic and parasympathetic autonomic nervous 
chains [1]. Head and neck paragangliomas (formerly, called glomus tumors) are derived 
from parasympathetic paraganglia, arising in the vagal and carotid bodies, jugulotym-
panic region (middle ear), orbit, or nasal cavity. They are nonchromaffin tumors (negative 
staining to chromium salts) and usually nonfunctional with the exception of a minority 
of these tumors (20–30%) that produce mostly methoxytyramine [2, 3]. Head and neck 
paragangliomas demonstrate usually a slow growth rate benign in nature with symptoms 
dependent on their location. As a result, they can cause clinical signs of compression and 
infiltration of adjacent neurovascular structures, such as cranial nerve palsy, hearing loss, 
and tinnitus [4].
Sympathetic paragangliomas are found in the mediastinum (from the thoracic sympathetic 
nervous chain), pre- and paravertebral autonomic nervous chains and para-aortic sympa-
thetic chains of the thorax, abdomen, and pelvis, including the organ of Zuckerkandl. These 
tumors often secrete catecholamines, especially norepinephrine, and are chromaffin-positive 
tumors. Due to their catecholamine secretory profile, pheochromocytomas and sympathetic 
paragangliomas can share the same clinical symptoms with the “the classic triad” of pal-
pitations, diaphoresis, and headache. Clinical signs can appear suddenly or be precipitated 
by physical activity, drugs (e.g. metoclopramide and glucocorticoids), foods containing tyra-
mine, diagnostic procedures, or micturition [5].
Pheochromocytomas and paragangliomas affect about 1 in 2500–6500 persons, but this inci-
dence may be more significant because of this disease diagnosis made after the person’s 
death [6]. Pheochromocytomas are found in approximately 4–5% of adrenal incidentalomas, 
and together with sympathetic paragangliomas, can be a secondary cause of hypertension 
in about 0.2–0.4% of the cases [7]. Paragangliomas can appear in all ages, but their highest 
incidence is between 40 and 50 years with no sex differences.
Although mostly benign, 10–15% of such tumors are malignant, consisting of metastatic 
spread of chromaffin cells especially in the liver, lungs, bone, and lymph nodes [8]. Despite 
much investigation, no definite biochemical, genetic, or histological markers to determine 
the malignant character of these particular neuroendocrine tumors has been identified. In 
this regard, the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) was created 
to predict the malignant character of pheochromocytomas with a PASS score of <4 sug-
gesting benignity, whereas a PASS score >4 indicating a potentially malignant tumor [9]. 
Nevertheless, a large retrospective study indicated no correlation of predictive risk and 
PASS score for malignancy [10]. Moreover, Ki-67 index of proliferation used commonly as a 
marker of malignancy in other tumors demonstrated no utility for distinguishing between 
benign or malignant pheochromocytomas and paragangliomas [11]. In addition, studies 
have revealed certain factors that predict malignancy for pheochromocytomas and para-
gangliomas: the extra-adrenal tumors in the mediastinum or the organ of Zuckerkandl, 
tumor size >5 cm, increased expression of angiogenesis-related genes by immunohisto-
chemistry, increased plasmatic levels of 3-methoxytyramine or chromogranin A, younger 
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age at  diag nosis, and identification of a SDHB mutation [12–15]. This chapter summarizes 
recent data regarding pheochromocytomas and paragangliomas with a focus on genetics. 
Furthermore, a genetic testing algorithm is proposed for the clinical management of such 
patients with these tumors.
2. Genetics of pheochromocytomas and paragangliomas
Before 2000, pheochromocytomas and paragangliomas were thought to follow the 10% 
rule: 10% familial, 10% bilateral, 10% extra-adrenal, 10% malignant, 10% children, 10% not 
hypertensive, and 10% calcified. It was previously believed that familial pheochromocyto-
mas and paragangliomas were caused by three gene mutations that determined three distinct 
clinical syndromes: multiple endocrine neoplasia type 2 (MEN2) syndrome involving RET 
proto-oncogene mutations, neurofibromatosis type I caused by NF1 gene mutations and von 
Hippel-Lindau disease produced by VHL gene mutations. Recent studies, however, reveal 
that 30–40% from pheochromocytomas and paragangliomas have an underlying genetic 
pathogenesis, and some sporadic tumors are caused by somatic mutations in 10–24% of the 
cases [16, 17].
Currently, more than 21 genes (RET, NF1, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2, 
MAX, TMEM127, HIF2A, KIF1Bβ, H-RAS, K-RAS, PHD2/EGLN1, IDH, ATRX, MDH2, 
PHD1, FH, and BAP1) are known to cause hereditary pheochromocytomas and para-
gangliomas. By the main signaling pathways, these genes have been grouped into two 
clusters:
1. Cluster 1, a pseudohypoxic group, referring to mutations in VHL, HIF2A, SDHx, EGLN1/
PHD2, IDH, MDH2, and FH genes
2. Cluster 2, a kinase receptor-signaling group of genes, involving mutations in NF1, RET, 
MAX, TMEM127, and KIF1B genes.
Recent studies have demonstrated that the two clusters are connected by particular signal-
ing pathways, all leading to tumorigenesis of pheochromocytomas and paragangliomas [18]. 
This elevated percentage of tumors with molecular pathogenesis indicates genetic testing 
as a mandatory step in the clinical management of patients with pheochromocytomas and 
paragangliomas.
2.1. Syndromic tumors
2.1.1. RET proto-oncogene
The REarranged during Transfection (RET) proto-oncogene is located on chromosome 10, 
and its translated protein is a transmembrane receptor from the tyrosine kinase family that 
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controls cellular growth, differentiation, and apoptosis. Germline mutation of RET activates 
this RET receptor with “gain of function.” This activation consequently leads to cell prolifera-
tion, causing an autosomal-dominant syndrome called multiple endocrine neoplasia type 2 
(MEN2). This syndrome is classified into two subcategories: MEN2A and MEN2B. MEN2A 
syndrome is further divided in four types: classical MEN2A, MEN2A associated with cutane-
ous lichen amyloidosis, MEN2A associated with Hirschprung’s disease, and familial medul-
lary thyroid cancer (FMTC).
The classical form of MEN2A syndrome is most frequent, occurring in approximately 90% of 
cases. It is characterized by medullary thyroid carcinoma (MTC) in 95% of cases, pheochro-
mocytoma in 50% of cases and hyperparathyroidism in 15–30% of cases. FMTC is represented 
by this thyroid cancer as the only clinical feature [5]. MEN2B syndrome is composed of MTC 
in all the cases, and pheochromocytoma in half of patients together with intestinal ganglio-
neuromas, multiple mucosal neuromas, and marfanoid habitus.
The MEN2 subcategories are linked with the RET gene defects. Most mutations of the RET 
gene in MEN2A and FMTC patients involve codons: 609, 611, 618, 620 (exon 10) or 630, and 
634 (exon 11). The mutation at codon 634, consisting in a majority of cases in the substitu-
tion of the amino acid cysteine to arginine, is the most frequent genetic defect in patients 
with MEN2A syndrome who have a high risk of pheochromocytoma. Regarding MEN2B, the 
majority of cases are determined by the codon 918 mutation (exon 16), leading to the substitu-
tion of methionine to threonine. Additionally, rare mutations in codon exon 14 and 15 have 
been associated with this type of MEN2 [19].
Pheochromocytomas associated with MEN2A and MEN2B syndromes are frequently 
benign and bilateral in a majority of cases at a young age diagnosed between 30 and 40 
years. The malignancy rate is less than 1–5%. The secretory profile is characterized by 
hypersecretion of epinephrine, caused by the overexpression of phenylethanolamine-N-
methyltransferase [16].
2.1.2. Neurofibromatosis type 1 tumor suppressor gene
Neurofibromatosis type 1 (NF1) syndrome, also called von Recklinghausen’s disease, is an 
autosomal dominant condition caused by mutations of the large neurofibromatosis type 1 
tumor suppressor gene (NF1). This gene is located on chromosome 17q11.2 and encodes for 
the protein neurofibromin, which enters nervous cells (e.g., neurons, Schwann cells, and oli-
godendrocytes), leukocytes, keratinocytes, and adrenal medulla [5].
NF1 gene defects can cause the inhibition of RAS signaling cascade, acceleration of phos-
phoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and mammalian tar-
get of rapamycin (mTOR) pathways. As a result, NF1 defects play a role in the alteration of 
cell growth, differentiation, migration, and apoptosis. Nevertheless, more than a half of NF1 
patients present de novo defects of the NF1 gene. Diagnosis of NF1 is based on clinical criteria 
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(at least two): six or more café- au- lait spots, two or more iris hamartomas (Lisch nodules), 
two or more cutaneous neurofibromas, optic-nerve glioma, freckling in the axilla, neck, or 
inguinal, pseudoarthrosis or dysplasia of the sphenoid bone, and a first-degree family mem-
ber with a diagnosis of NF1.
Patients with NF1 also have an increased risk for brainstem gliomas, astrocytomas, gastroin-
testinal stromal tumors, rhabdomyosarcomas, chronic myeloid leukemias, and pheochromo-
cytomas. The incidence of pheochromocytomas in NF1 patients is approximately 0.1–5.7%, 
typically by 42 years of age. Cases of sympathetic paragangliomas are very rarely reported. 
Most pheochromocytomas are unilateral, benign, and have an epinephrine secretory profile. 
The rate of malignancy for pheochromocytomas in NF1 patients is approximately 12%, a little 
higher than in MEN2, and VHL patients [20, 21].
2.1.3. Von Hippel-Lindau disease tumor suppressor gene
Von Hippel-Lindau (VHL) tumor suppressor gene is located on the short arm of chromo-
some 3, and this gene encodes for VHL protein that controls the actions of hypoxia-induc-
ible factor alpha (HIFα). Germline mutations of this tumor suppressor gene cause VHL 
disease, an autosomal dominant disorder that comprises a large variety of tumors: retinal 
angiomas, cerebellar and spinal hemangioblastomas, clear cell renal carcinoma, neuroen-
docrine tumors of the pancreas, epididymal cystadenomas, cysts of the broad ligament, 
endolymphatic sac tumors, pheochromocytomas, and paragangliomas. Depending on the 
presence of pheochromocytomas and paragangliomas, VHL disease is divided into type 1 
and type 2. Type 1 VHL disease is the most common form, characterized by the absence 
of pheochromocytomas and paragangliomas. Conversely, type 2 VHL disease is distin-
guished by the development of pheochromocytomas and paragangliomas. Type 2 VHL 
disease is further classified into three subcategories: 2A without clear renal cell carcinoma, 
2B with clear renal cell carcinoma, and 2C with only pheochromocytomas and paragan-
gliomas [16].
VHL gene mutations are variable, and >500 germline transformations have been described 
(i.e., insertions, deletions, missense, nonsense, and splice site mutations) with a rate of 
occurrence of de novo mutations of up to 20%. In type 1 VHL disease, the most frequently 
encountered are deletions and nonsense mutations, whereas in type 2 VHL diseases, the most 
common are missense mutations. It is important to note that missense mutations in codon 167 
increase patient’s risk to develop pheochromocytomas.
Sympathetic head and neck paragangliomas cases are rarely reported. Pheochromocytomas 
develop in 10–20% of VHL patients, more than a half of them being bilateral, with a young age of 
onset around 30 years. Pheochromocytomas and paragangliomas within this disorder secrete 
mainly norepinephrine due to the absence of the phenylethanolamine N-methyltransferase. 
Furthermore, malignant pheochromocytomas have been reported in few cases, lower than 5% 
of VHL patients [22].
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2.1.4. Genes encoding succinate dehydrogenase mitochondrial complex
Gene mutations encoding for the succinate dehydrogenase (SDH) complex (SDHA, SDHB, 
SDHC, SDHD, and the cofactor SDHAF2) lead to clinical manifestations of the familial para-
ganglioma (PGL) syndromes (PGL1, PGL2, PGL3, and PGL4). The SDH complex plays a role 
in the Krebs cycle and electron transport chain, and its genetic defects effect the increase of 
succinate and reactive oxygen species and stabilization of hypoxia-inducible factor 1 (HIF-1). 
Mutations of the SDH complex resemble VHL disease where the hypoxia signaling pathways 
are activated [23].
2.1.4.1. PGL 1 syndrome
Paraganglioma 1 (PGL1) syndrome is an autosomal-dominant condition, with maternal 
imprinting, caused by SDHD gene defects. This particular gene is localized on the long arm 
of chromosome 11. The clinical characteristics of this syndrome are multifocal nonsecretory 
parasympathetic head and neck paragangliomas and, less commonly, sympathetic thoracic or 
abdominal paragangliomas. Furthermore, pheochromocytomas have rarely been described. 
Tumor malignant transformation for SDHD mutation carriers is <5% [24].
2.1.4.2. PGL 2 syndrome
Familial paraganglioma 2 (PGL2) syndrome is a rare autosomal-dominant transmitted con-
dition, with maternal imprinting, caused by genetic defects in SDHAF2/SDH5 gene that is 
localized on the long arm of chromosome 11. The gene product is succinate dehydrogenase 
assembly factor 2 (SDHAF2), which ensures the flavination of SDHA subunit. Studies have 
reported that mutations carriers have exclusively multifocal head and neck paragangliomas 
with an early onset from 30 to 40 years [25].
2.1.4.3. PGL 3 syndrome
Familial paraganglioma 3 (PGL3) syndrome, also with an autosomal dominant mode of trans-
mission, is caused by SDHC gene mutations that are localized on the long arm of chromosome 
1. This disorder is characterized by the presence of benign parasympathetic head and neck 
in paragangliomas up to 4% of patients. However, few cases of pheochromocytomas and 
sympathetic paragangliomas have been described. The biochemical phenotype is frequently 
associated with noradrenergic or dopaminergic secretion, but they can also be nonsecreting 
tumors. The malignancy rate of these tumors is very low [26].
2.1.4.4. PGL 4 syndrome
The most frequently encountered modification, germline mutations of the SDHB gene found 
in locus 1 p36.13 cause familial paraganglioma 4 (PGL4) syndrome. The clinical manifes-
tations of this disorder consist in thoracic, abdominal, and pelvic catecholamine-secreting 
paragangliomas, parasympathetic head and neck paragangliomas. Tumors associated with 
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SDHB gene mutations are frequently multiple, large, presenting a noradrenergic or dopami-
nergic secretory profile. Diagnosis is usually made at a young age (approximately 30 years), 
and they are linked to a high risk of developing metastases (ranging from 30 to 72% of cases). 
As a result, all patients with malignant pheochromocytomas and paragangliomas should 
undergo genetic screening, searching initially for SDHB gene modifications. Patients with 
PGL4 syndrome present a high risk for developing clear cell renal carcinoma, neuroblas-
toma, papillary thyroid carcinoma, breast neoplasms and gastrointestinal stromal tumors 
(GIST) [18, 21, 23, 27, 28].
SDHA gene mutations localized on the short arm of chromosome 5 which were initially 
found only in homozygous carriers, were linked to the rare juvenile encephalopathy rec-
ognized also as Leigh syndrome. Additionally, paragangliomas were described in the het-
erozygous carriers of the SDHA gene mutations, having a malignancy rate of 0–14%. [29]. 
Germline mutations of the SDHB, SDHC, and SDHD genes were also identified in the 
Carney-Stratakis dyad that consists of gastrointestinal stromal tumors (GIST) and para-
gangliomas, and the Carney triad, composed of paragangliomas, GIST, and pulmonary 
chondromas. The secretory profile of SDHx-related paragangliomas is characterized by 
an overproduction of norepinephrine together with dopamine, dopamine hypersecretion 
(or its metabolite 3-methoxytyramine) only, or a silent biochemical phenotype [5, 23, 30].
2.2. Nonsyndromic tumors
2.2.1. Other susceptibility genes
2.2.1.1. TMEM127 gene
The TMEM127 gene is localized on the long arm of chromosome 2, which encodes for trans-
membrane protein 127. Expression of this gene is associated with endosomes, lysosomes, 
and Golgi complex, acting as a negative factor of mTOR kinase pathways that modulates cell 
growth and apoptosis. Mutations of this gene induce the development of pheochromocytoma 
(unilateral or bilateral), abdominal and head and neck paragangliomas with adrenergic or 
noradrenergic biochemical phenotypes. Further studies report a 2% prevalence of TMEM127 
germline mutations in patients with pheochromocytomas and paragangliomas at a mean age 
of 43 years. Risk for malignant transformation is approximately 1%. Other tumors such as 
breast and papillary thyroid carcinoma have been described in patients carrying this gene 
mutation [5, 18, 31, 32].
2.2.1.2. MAX gene
The MYC-associated factor X (MAX) gene localized on the short arm of chromosome 14 
encodes for MAX protein, and its main role is in the modulation of cell growth and apop-
tosis as a component of the MYC-MAX-MXD1 complex. MAX gene germline defects have 
been described in patients with pheochromocytomas and paragangliomas. The tumors are 
frequently bilateral with a mean age of onset at 32 years. They also present with an increased 
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malignant potential (25% of patients). Additionally, mutations of MAX gene have a paternal 
mode of transmission with maternal imprinting. They lead to the development of tumors 
with a norepinephrine secretory profile [5, 18, 33].
2.2.1.3. HIF2A gene
Hypoxia-inducible factor 2-alpha (HIF2A) gene mutations found in the locus 2p21 have 
recently been correlated with the development of pheochromocytomas and paragangliomas. 
HIF2A gene mutations determine a decreased rate of HIF2α protein degradation. They lead to 
an enhanced action of vascular endothelial growth factor A (VEGF-A) and erythropoietin that 
regulate cell proliferation, angiogenesis, and erythropoiesis. Somatic HIF2A gene mutations 
have been described in patients who presented with multiple pheochromocytomas and para-
gangliomas with a noradrenergic secretory profile, polycythemia, and somatostatinomas, 
which comprise the clinical features of the recently described Pacak-Zhuang syndrome. Of 
note, all patients with this syndrome were women, but further studies are required in order 
to establish the genetic basis [18, 34].
2.2.1.4. EGLN1/PHD2 gene
The egg-laying-defective nine 1 gene (EGLN1) also named prolyl hydroxylase domain 2 
(PHD2) gene is located on chromosome 1q42.1, and encodes for the EGLN1/PHD2 protein 
that hydroxylates HIFα protein. Germline mutations of EGLN1/PHD2 gene have been associ-
ated with the development of multiple sympathetic abdominal paragangliomas and erythro-
cytosis [18, 35].
2.2.1.5. KIF1Bβ gene
The kinesin family 1Bβ gene (KIF1Bβ) is located on chromosome 1p36.22 and its product 
plays an important role in regulating cell apoptosis. Very rare cases of patients with germline 
KIF1B gene mutations have been reported to have unilateral or bilateral pheochromocytomas, 
neuroblastoma, ganglioneuroma, medulloblastoma, leiomyosarcoma, and lung adenocarci-
noma [5, 18, 36].
2.2.1.6. IDH gene
The isocitrate dehydrogenase (IDH) gene is located on chromosome 2q33.3, and its mutations 
are frequently associated with glioblastoma multiforme. Studies conducted on patients with 
pheochromocytomas and paragangliomas indicate only one somatic mutation of the IDH 
gene associated in the development of carotid paragangliomas [18, 37].
2.2.1.7. FH gene
The fumarate hydratase (FH) gene is found on chromosome 1q43 and its germline mutation has 
been reported in one patient with a pheochromocytoma and noradrenergic secretory profile. 
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Furthermore, FH gene mutations have also been reported in patients with clear cell renal carci-
noma and leiomyomatosis [11, 18, 38].
2.2.1.8. BAP1 gene
Germline mutations of BRCA-1 associated protein-1 (BAP1) gene located on chromosome 
3p21.1 have been reported in a limited number of patients with paragangliomas. Moreover, 
BAP1 mutations were identified in some patients with meningioma, melanoma, and mesothe-
lioma, but correlations with familial paragangliomas require further studies [18, 39].
2.2.1.9. HRAS and KRAS genes
The RAS genes (Harvey rat sarcoma—H-RAS virus gene located on chromosome 11p15, and 
Kirsten rat sarcoma virus gene—K RAS found on chromosome 12p12.1) are the most com-
mon oncogenes associated with malignancies. H-RAS and K-RAS gene mutations cause the 
constitutive activation of the GTPase domain of RAS, inducing cell growth through activated 
RAS-ERK (extracellular signal-regulated kinase) pathway. Somatic mutations in H-RAS and 
K-RAS have been described in limited cases of pheochromocytomas and paragangliomas 
with adrenergic or noradrenergic biochemical phenotype. Recently, one study regarding 
pheochromocytomas and paragangliomas stated that 6.9% of patients had somatic H-RAS 
mutations [40, 41].
2.2.2. Miscellaneous
One family with a germline mutation of Malate Dehydrogenase type 2 (MDH2) gene with 
multiple metastatic paragangliomas producing norepinephrine has been described [41, 42]. 
Furthermore, somatic mutations of Alpha Thalassemia/Mental Retardation Syndrome X-Linked 
(ATRX) gene have been described in aggressive cases of pheochromocytomas and paragangli-
omas. This gene, localized on the X chromosome, plays an important role in telomere function 
[41, 43]. Moreover, a novel germline mutation involving prolyl hydroxylase domain 1 (PHD1) 
also known as egg-laying-defective nine 2 gene (EGLN2) mutation was reported in one case of 
pheochromocytoma/paraganglioma, and polycythemia [41, 44].
Recent studies have also stated that the following genes play roles in the development of 
pheochromocytomas and paragangliomas: glial cell-derived neurotrophic factor (GDNF) 
localized on 5p13.2, guanine nucleotide binding protein (g protein) alpha stimulating 
(GNAS) found on 20q13.32, cyclin-dependent kinase inhibitor 2a (CDKN2A) localized on 
9p21.3, breast cancers BRCA 1 and 2 found on 17q21.31 and 13q13.1, respectively, lysine 
methyltransferase 2d (KMT2D) found on 12q13.12, and tumor protein p53 localized on 
17p13.1 [18, 46–48, 50].
All genes currently known to be involved in the pathogenesis of pheochromocytomas and 
paragangliomas, specifying the chromosomal location of the gene, hormonal secretory pro-
file, malignancy risk, and the main clinical characteristics of the patients and associated dis-
eases are summarized in Table 1 [5, 16–18, 21, 22, 27, 30, 41, 50, 55–59].
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 Gene Locus Syndrome Hormonal secretory 
profile
Malignancy risk Clinical features and associated tumors
RET 10q11.2 MEN 2 Adrenergic Low 1–5% Frequently benign, bilateral pheochromocytomas associated with
• MEN2A: Medullary thyroid carcinoma (95%) and hyperpara-
thyroidism (15–30%)
• MEN2B: marfanoid habitus; mucosal
• Ganglioneuromas
NF1 17q11.2 NF1 Adrenergic 12% Mostly unilateral, benign pheochromocytomas and very rare 
sympathetic paragangliomas, associated with:
• Café- au- lait spots
• Cutaneous neurofibromas
• Iris hamartomas (Lisch nodules)
• Optic nerve gliomas
• Inguinal or axillary freckles
• Sphenoid bone dysplasia or pseudoarthrosis
VHL 3p25.5 VHL Noradrenergic Less than 5% Usually bilateral, benign pheochromocytomas and rare 
sympathetic or parasympathetic paragangliomas together with
• Cerebellar and spinal hemangioblastomas
• Retinal angiomas
• Epididymal cystadenomas
• Cysts of the broad ligament
• Endolymphatic sac tumors
• Clear cell renal carcinoma
• Islet cell tumors of pancreas
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Gene Locus Syndrome Hormonal secretory 
profile
Malignancy risk Clinical features and associated tumors
SDHA 5p15 Unknown 0–14% Pheochromocytomas and paragangliomas
• Leigh syndrome in homozygous patients
SDHAF2/SDH5 11q13.1
Paternal 
transmission
PGL2 Unknown Unknown Head and neck paragangliomas
SDHB 1p36.13 PGL4 Noradrenergic or 
dopaminergic
30–72% Frequently malignant pheochromocytomas and sympathetic or 
parasympathetic head and neck paragangliomas associated with
• Gastrointestinal stromal tumors
• Renal cell carcinoma
• Breast carcinoma
• Papillary thyroid carcinoma
• Neuroblastoma
SDHC 1q21 PGL3 Noradrenergic, 
dopaminergic or 
silent
Low Mostly benign parasympathetic head and neck paragangliomas 
and rarely cases of pheochromocytomas and sympathetic 
paragangliomas
SDHD 11q23
Paternal 
transmission
PGL1 Noradrenergic, 
dopaminergic or 
silent
Less than 5% Frequently multiple head and neck paragangliomas, 
less commonly sympathetic paragangliomas and rarely 
pheochromocytomas
MAX 14q23.3
Paternal 
transmission
– Adrenergic or 
noradrenergic
25% Frequently bilateral pheochromocytomas and paragangliomas
TMEM127 2q11.2 – Adrenergic or 
noradrenergic
Low 1% Pheochromocytomas (unilateral or bilateral), sympathetic and 
head and neck paragangliomas
• Papillary thyroid carcinoma
• Breast carcinoma
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Gene Locus Syndrome Hormonal secretory 
profile
Malignancy risk Clinical features and associated tumors
HIF2A 2p21 Pacak-Zhuang Noradrenergic or 
adrenergic
Unknown Multiple pheochromocytomas or paragangliomas associated with:
• Multiple somatostatinomas
• Polycythemia
IDH 2q33.3 – Unknown Unknown Carotid paragangliomas with
• Glioblastoma multiforme
FH 1q43 – Noradrenergic Unknown/
potentially high
Pheochromocytomas associated with
• Leiomyomatosis
• Clear renal cell carcinoma
KIF1Bβ 1p36.2 – Unknown Unknown Unilateral or bilateral Pheos, associated with
• Neuroblastoma
• Ganglioneuroma
• Medulloblastoma
• Leiomyosarcoma
• Lung adenocarcinoma
PHD2/EGLN1 1q42.1 – Unknown Unknown Multiple paragangliomas associated with
• Erythrocytosis
H-RAS
K-RAS
11p15
12p12
– Adrenergic or 
noradrenergic
Unknown Pheochromocytomas and paragangliomas
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Gene Locus Syndrome Hormonal secretory 
profile
Malignancy risk Clinical features and associated tumors
BAP1 3p21.1 – Unknown Unknown Paragangliomas associated with
• Meningioma
• Melanoma
• Mesothelioma
ATRX Xq21.1 – Unknown Unknown Pheochromocytomas and paragangliomas
PHD1/EGLN2 19q13.2 – Unknown Unknown Pheochromocytomas and paragangliomas associated with
• Polycythemia
MDH2 7q11.23 – Noradrenergic Unknown Multiple metastatic paragangliomas
Table 1. Genotype-phenotype correlations for pheochromocytomas and paragangliomas.
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3. Guidelines for the genetic diagnosis of pheochromocytomas and 
paragangliomas
It is currently recognized that 30–40% of pheochromocytomas and paragangliomas are caused 
by the aforementioned genetic mutations, and several studies have concluded that all patients 
with such tumors should be genetically tested [45, 46]. Hereditary pheochromocytomas and 
paragangliomas are frequently multifocal, recurrent and, in particular cases, have a high risk 
for malignant transformation. Therefore, early diagnosis may assure more effective treatment 
and improved prognosis. Genetically, inherited syndromes are also commonly associated with 
other neoplasms, justifying the need for early diagnosis and treatment. Furthermore, the iden-
tification of a germline defect within a family can ensure early diagnosis, treatment, and better 
clinical outcomes for other family members. Finally, hereditary pheochromocytomas and para-
gangliomas should be suspected in all patients, but these cases presenting the following clinical 
characteristics should be investigated first: patients with clinical features of a specific syndrome, 
age <45 years, patients with multiple, recurrent, or malignant tumors, and also individuals with 
a family history or personal medical history of head and neck paragangliomas [45–47].
Management of such patients should start with a careful clinical examination including cuta-
neous and retinal examination followed by a genetic work-up (family history and pedigree). 
Advanced medical techniques such as next-generation and whole genome sequencing rep-
resent the optimal genetic strategies for discovering gene mutations [46–48]. Several studies 
have proposed different algorithms for genetic diagnosis in order to prioritize gene testing 
due to its high price and lack of availability. Patient’s age and family history, together with 
tumor secretory profile and position are considered valuable in the determination for genetic 
testing. The authors propose an algorithm (Figure 1) for genetic testing that comprises infor-
mation and clinical data from the latest medical reports [16–18, 27, 30, 41, 45–50].
Patients with a known familial disorder, syndromic lesions, or both should be tested for the 
appropriate gene. Specific clinical characteristics of a particular syndrome should guide the test-
ing protocol. For example, the occurrence of MTC together with pheochromocytoma is sugges-
tive for MEN2 (RET gene); the presence of café- au- lait spots, Lisch nodules, would indicate NF1 
gene testing and the presence of hemangioblastomas significant for VHL gene testing [19–22]. In 
addition, the association of diseases such as GIST, renal clear cell carcinoma, breast, and thyroid 
carcinoma should guide the clinician to test SDH gene mutations, especially SDHB [23, 27, 28, 30].
Recent discoveries have shown that the order of tested genes in nonsyndromic, nonfamilial cases 
can be based on the histological evaluation, location, and biochemical phenotype of pheochro-
mocytomas and paragangliomas. Biochemical testing is the least expensive diagnostic method, 
but it is often overlooked by physicians. There are several types of biochemical phenotypes:
a. The adrenergic phenotype consisting of epinephrine or metanephrine secretion orient the 
diagnosis first to MEN2 syndrome or NF1, then second to TMEM127, HIF2A, MAX, H-RAS, 
and K-RAS genes.
b. The noradrenergic phenotype, resulting in normetanephrines and norepinephrine pro-
duction, is typical for pheochromocytomas within VHL disease or for SDHB-related 
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paragangliomas. However, mutations of SDHC, SDHD, MAX, HIF2A, TMEM127, FH, 
MDH2, K-RAS, and H-RAS genes have been reported.
c. A mixed phenotype characterized by the production of both epinephrines/metanephrines 
and norepinephrines/normetanephrines indicate the involvement of HIF2A, TMEM127, 
H-RAS, K-RAS, and MAX genes.
d. A dopaminergic biochemical phenotype should indicate first, initial SDHB and SDHD 
gene testing, and second, screening for SDHC gene [2, 3, 51].
e. A silent phenotype with no catecholamines/metanephrines production is associated with 
SDHx mutations.
Bilateral pheochromocytomas are frequently described in RET and VHL gene mutations, and 
therefore, testing of these sites should be considered as a first step [19, 21, 41]. Afterward, if nega-
tive, mutations in SDHB, SDHD, MAX, and TMEM127 genes should be evaluated [30–33, 52, 53].
Sympathetic paragangliomas are more commonly associated with SDHB, SDHD, and VHL 
genes mutations; and less frequently with SDHA, SDHC, TMEM127, NF1, and EGLN1/PHD2 
gene mutations [24–28, 53, 54]. Parasympathetic head and neck paragangliomas are com-
monly described in SDHB, SDHC, and SDHD gene mutation carriers, and rarely associated 
with SDHAF2, VHL, and TMEM127 gene mutations [54, 55]. Malignant pheochromocytomas 
and paragangliomas have been associated with germline mutations of the SDHB gene, but if 
 Figure 1. Genetic testing algorithm.
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negative, testing for SDHD, SDHA, VHL, MAX, and NF1 gene mutations should be consid-
ered [4, 5, 11–14, 56–59]. Moreover, paternal transmission mode of pheochromocytomas and 
paragangliomas corresponding to maternal imprinting leads to genetic testing toward the 
SDHD, SDHAF2, and MAX genes [23–25, 30, 33].
4. Conclusions
Recent progress in the better understanding of pheochromocytomas and paragangliomas 
have revealed 30–40% of these tumors have underlying genetic mutations. More than 21 
genetic mutations involving the following genes: RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, 
NF1, VHL, MAX, H-RAS, K-RAS, KIF1B, TMEM127, HIF2A, IDH, FH, PHD2/EGLN1, PHD1, 
MDH2, BAP1, and ATRX have been linked to the development of pheochromocytomas and 
paragangliomas. Due to cost and lack of availability of the next-generation sequencing tests 
used for genetic screening, it is important to classify the risks by other clinical means as well.
Recent studies recommend considering the following criteria: tumor type, position, presence 
of metastases, secretory profile, or any particular clinical feature. As a result, establishing a 
genetic testing protocol based on which physicians can guide their diagnosis and treatment is 
essential. The advantages of the detection of inherited mutations in cases of pheochromocy-
tomas and paragangliomas can provide a proper diagnosis and treatment with an improved 
clinical outcome for the patient, as well as an early diagnosis for family members. In cases 
of familial pheochromocytomas and paragangliomas, distant metastases and additional can-
cers can develop, highlighting the importance of early diagnosis and treatment. The strong 
genetic determinism of pheochromocytomas and paragangliomas emphasize the need for 
further studies to better understand the pathogenesis and malignant transformation of these 
particular tumors, which may have an important role in the development of future treatment 
options.
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